A recent clinical trial of epidermal growth factor receptor (EGFR)‐targeted PIT in patients with inoperable head and neck cancer has shown promise in a Phase 1/2 clinical trial (NCT02422979). This evidence concerns the gene EGFR and head and neck cancer.